Drug-maker Glenmark is set to benefit from the settlement of its patent litigation with Merck on ezetimibe, the cholesterol-modifying drug sold by the latter as Zetia. Zetia is a blockbuster product, with its sales in the
The settlement gives Glenmark a four-and-a-half-month period of exclusive sales that gets shared with Par Pharmaceutical, following a deal on the same drug earlier this month. The settlement with Merck ends the lawsuit involving a challenge by Glenmark – as it sought to launch a generic version of Zetia before the April 2017 expiration of the patent exclusivity on the drug.
The agreement will now allow Glenmark to launch its product in the
Glenmark looks set to get about $150 million when generic Zetia hits the market in 2016, despite the licensing and supply agreement with Par Pharma. Under the existing agreement, Par had paid Glenmark for exclusive rights to market, sell and distribute ezetimibe in the
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: